A series of 143 salicylanilidessubstituted in positions 4 and 5 and in positions 3′ and 4′ was synthesized. The compounds were evaluated for in vitro antimycobacterial activity against Mycobacterium tuberculosis, Mycobacterium kansasii, and Mycobacterium avium. To describe the structure‐antimycobacterial activity relationships (QSARs), an approach based on the combination of the Free‐Wilson and Hansch
pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGFR proteintyrosinekinase and a putative binding mode of 4-anilinoquinazoline suggest that a salicylic acid function could serve as the pharmacophore replacement of a pyrimidine ring. Superpositions by CAMM of salicylanilides with the potent EGFR tyrosinekinaseinhibitor 4-[(3'-chlorophenyl)amino]-6,7-dimethoxyquinazoline